Pennant Group, Inc.
Current role
PNTG
Jason P. Steik
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jason P. Steik
The proxy statement of Pennant Group, Inc. reports total compensation of $1,833,286 for Jason P. Steik in fiscal 2025, including a base salary of $283,654. Disclosed compensation is on record for 5 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Pennant Group, Inc. (PNTG)
Proxy statement
CurrentStart not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Pennant Group, Inc.
Other people whose current roles at this company are on record from its filings.
- Brent Guerisoli CEO, Board Member
- Barry Smith Chairman
- Lynette B. Walbom CFO
- Lynette Walbom CFO
- John Gochnour COO
- Kirk Cheney General Counsel
- Barry M. Smith Board Member
- Christopher R. Christensen Board Member
- Gregory K. Morris Board Member
- John G. Nackel Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Pennant Group, Inc. (PNTG) | Chief Clinical Officer The annual amounts shown are the amounts of total compensation cost which will be recognized over the five-year vesting period related to restricted stock awards which were granted during fiscal years 2025, 2024, and 2023, as a result of the adoption of ASC 718. For a discussion of valuation and forfeiture assumptions, see Note 12, Options and Awards, in our consolidated financial statements in our 2025 Form 10-K. In addition, a portion of the amounts paid under the 2025 annual executive incentive program to Brent J. Guerisoli, Lynette B. Walbom, John J. Gochnour, and Kirk S. Cheney, in the amounts of $662,117, $471,922, $613,016, and $134,886, respectively, were made in the form of fully vested restricted stock awards. In 2024, a portion of the amounts paid under the annual executive incentive program to Brent J. Guerisoli, Lynette B. Walbom, and John J. Gochnour, in the amounts of $106,657, $59,997, and $83,338, respectively, were made in the form of fully vested restricted stock awards. The annual amounts shown are the amounts of total compensation cost which will be recognized over the five year vesting period related to options to purchase common stock which were granted during fiscal years 2025, 2024, and 2023, as a result of the adoption of ASC 718. These awards are not immediately exercisable. For a discussion of valuation and forfeiture assumptions, see Note 12, Options and Awards, in our consolidated financial statements in our 2025 Form 10-K. Represents amounts earned under the executive incentive program in the corresponding year but paid in the first quarter of the following year. Details about the amounts in the “All Other Compensation” column for fiscal year 2025 are set forth in the table below: | $283,654 | $1,833,286 |
| 2024 | Pennant Group, Inc. (PNTG) | Chief Clinical Officer The annual amounts shown are the amounts of total compensation cost which will be recognized over the five-year vesting period related to restricted stock awards which were granted during fiscal years 2025, 2024, and 2023, as a result of the adoption of ASC 718. For a discussion of valuation and forfeiture assumptions, see Note 12, Options and Awards, in our consolidated financial statements in our 2025 Form 10-K. In addition, a portion of the amounts paid under the 2025 annual executive incentive program to Brent J. Guerisoli, Lynette B. Walbom, John J. Gochnour, and Kirk S. Cheney, in the amounts of $662,117, $471,922, $613,016, and $134,886, respectively, were made in the form of fully vested restricted stock awards. In 2024, a portion of the amounts paid under the annual executive incentive program to Brent J. Guerisoli, Lynette B. Walbom, and John J. Gochnour, in the amounts of $106,657, $59,997, and $83,338, respectively, were made in the form of fully vested restricted stock awards. The annual amounts shown are the amounts of total compensation cost which will be recognized over the five year vesting period related to options to purchase common stock which were granted during fiscal years 2025, 2024, and 2023, as a result of the adoption of ASC 718. These awards are not immediately exercisable. For a discussion of valuation and forfeiture assumptions, see Note 12, Options and Awards, in our consolidated financial statements in our 2025 Form 10-K. Represents amounts earned under the executive incentive program in the corresponding year but paid in the first quarter of the following year. Details about the amounts in the “All Other Compensation” column for fiscal year 2025 are set forth in the table below: | $269,344 | $1,010,594 |
| 2023 | Pennant Group, Inc. (PNTG) | Chief Clinical Officer The annual amounts shown are the amounts of total compensation cost which will be recognized over the five-year vesting period related to restricted stock awards which were granted during fiscal years 2025, 2024, and 2023, as a result of the adoption of ASC 718. For a discussion of valuation and forfeiture assumptions, see Note 12, Options and Awards, in our consolidated financial statements in our 2025 Form 10-K. In addition, a portion of the amounts paid under the 2025 annual executive incentive program to Brent J. Guerisoli, Lynette B. Walbom, John J. Gochnour, and Kirk S. Cheney, in the amounts of $662,117, $471,922, $613,016, and $134,886, respectively, were made in the form of fully vested restricted stock awards. In 2024, a portion of the amounts paid under the annual executive incentive program to Brent J. Guerisoli, Lynette B. Walbom, and John J. Gochnour, in the amounts of $106,657, $59,997, and $83,338, respectively, were made in the form of fully vested restricted stock awards. The annual amounts shown are the amounts of total compensation cost which will be recognized over the five year vesting period related to options to purchase common stock which were granted during fiscal years 2025, 2024, and 2023, as a result of the adoption of ASC 718. These awards are not immediately exercisable. For a discussion of valuation and forfeiture assumptions, see Note 12, Options and Awards, in our consolidated financial statements in our 2025 Form 10-K. Represents amounts earned under the executive incentive program in the corresponding year but paid in the first quarter of the following year. Details about the amounts in the “All Other Compensation” column for fiscal year 2025 are set forth in the table below: | $257,726 | $720,996 |
| 2022 | Pennant Group, Inc. (PNTG) | Chief Clinical Officer The annual amounts shown are the amounts of total compensation cost which will be recognized over the five year vesting period related to stock awards which were granted during the year ended December 31, 2024, as a result of the adoption of ASC 718. These awards vest over five years. For a discussion of valuation and forfeiture assumptions, see Note 12, Options and Awards, in our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The annual amounts shown are the amounts of total compensation cost which will be recognized over the five year vesting period related to options to purchase common stock which were granted during the year ended December 31, 2024, as a result of the adoption of ASC 718. These awards are not immediately exercisable and vest over five years. For a discussion of valuation and forfeiture assumptions, see Note 12, Options and Awards, in our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Represents amounts earned under the executive incentive program in the corresponding year but paid in the first quarter of the following year. Details about the amounts in the “All Other Compensation” column for fiscal year 2024 are set forth in the table below: | $236,667 | $520,158 |
| 2021 | Pennant Group, Inc. (PNTG) | Chief Clinical Officer Jennifer L. Freemen stepped down from her role as interim Chief Financial Officer on May 22, 2023 and Lynette B Walbom took over the role of Chief Financial Officer on the same date. | $212,292 | $365,024 |
Recent activity
No call appearances or filed executive changes recorded yet.